source
- Jazz partners with AbCellera on $4 billion deal to develop next-generation T-cell engagers for solid tumorsJazz Pharmaceuticals disclosed a collaboration with AbCellera aimed at creating next-generation T-cell-engaging antibodies for solid tumors. Under the agreement Jazz will pay $56 million up front…
- Westlake-backed Vedana Therapeutics raises $46M to develop anti-PACAP migraine prevention drugsVedana Therapeutics, a new biotech formed out of stealth, announced it has secured $46 million in financing backed by Westlake. The capital will be used to advance its anti-PACAP antibody program a…